AnaptysBio, Inc. ANAB
47.77 USD -1.00 (-2.05%)
At closeNov 12, 2026, 4:00 PM EST
47.77 0.00 0.00%
After hours · Nov 12, 4:00 PM ET
47.68 Day range 48.87
22.06 52-week range 69.81
- YTD
- +47.80%
- 1 year
- +116.55%
News
zacks.com AnaptysBio, Inc. (ANAB) Misses Q3 Earnings and Revenue Estimates AnaptysBio, Inc. (ANAB) came out with quarterly earnings of $0.11 per share, missing the Zacks Consensus Estimate of $0.41 per share. This compares to earnings of $0.52 per share a year ago.
benzinga.com AnaptysBio Q3 EPS $0.11 Misses $ 0.51 Estimate, Sales $30.274M Miss $33.186M Estimate AnaptysBio (NASDAQ:ANAB) reported quarterly earnings of $0.11 per share which missed the analyst consensus estimate of $1.58 by 93.04 percent. This is a 78.85 percent decrease over earnings of $0.52…
globenewswire.com Anaptys Reports Fiscal First Quarter 2027 Financial Results and Provides Business Update SAN DIEGO, Nov. 12, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with Tesaro, a GSK company, and Quimilza…
globenewswire.com Anaptys Announces Participation in Upcoming Investor Conferences SAN DIEGO, Nov. 10, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with Tesaro, a GSK company, and Quimilza…
seekingalpha.com Riverwater Micro Opportunities Strategy Q3 2026 Portfolio Activity We initiated a position in 908 Devices, a maker of portable chemical detection instruments used by hazmat teams, law enforcement, firefighters, and the military. We initiated a position in Bowhead…
seekingalpha.com Diamond Hill Small-Mid Cap Fund Q3 2026 Contributors And Detractors The Fund declined 4.75% while the Russell 2500 Index declined 6.37%. Key contributors include Illumina, Revvity and Waystar. Key detractors include Regal Rexnord, Knife River and Red Rock Resorts.
zacks.com AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: Should You Buy? AnaptysBio (ANAB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
globenewswire.com Jemperli (dostarlimab) Approved in the U.S. as First and Only Immunotherapy for Adults with MSI-H/dMMR Locally Advanced Rectal Cancer SAN DIEGO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with Tesaro, a GSK company, and Quimilza…
benzinga.com JP Morgan Maintains Overweight on AnaptysBio, Lowers Price Target to $60 JP Morgan analyst Anupam Rama maintains AnaptysBio (NASDAQ:ANAB) with a Overweight and lowers the price target from $70 to $60.
benzinga.com HC Wainwright & Co. Reiterates Buy on AnaptysBio, Maintains $95 Price Target HC Wainwright & Co. analyst Joseph Pantginis reiterates AnaptysBio (NASDAQ:ANAB) with a Buy and maintains $95 price target.
benzinga.com Leerink Partners Maintains Outperform on AnaptysBio, Lowers Price Target to $81 Leerink Partners analyst David Risinger maintains AnaptysBio (NASDAQ:ANAB) with a Outperform and lowers the price target from $90 to $81.
zacks.com AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates AnaptysBio, Inc. (ANAB) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to a loss of $1.34 per share a year ago.
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Milestone Scientific (AMEX:MLSS) stock moved upwards by 11.8% to $0.44 during Monday's after-market session. The company's market cap stands at $36.9 million. Evotec (NASDAQ:EVO) stock rose…- benzinga.com AnaptysBio Q2 Adj. EPS $(0.11) Beats $(0.46) Estimate, Sales $27.488M Beat $21.675M Estimate AnaptysBio (NASDAQ:ANAB) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.46) by 76.09 percent. This is a 91.79 percent increase over losses of $(1.34)…
globenewswire.com Anaptys Announces Second Quarter and Transitional Fiscal Year 2026 Financial Results and Provides Business Update SAN DIEGO, Sept. 21, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with Tesaro, a GSK company, and Quimilza…
globenewswire.com Anaptys Announces Participation at the H.C. Wainwright 28th Annual Global Investment Conference SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today…
defenseworld.net 16,500 Shares in AnaptysBio, Inc. $ANAB Bought by Canada Pension Plan Investment Board Canada Pension Plan Investment Board purchased a new stake in AnaptysBio, Inc. (NASDAQ: ANAB) in the second quarter, according to the company in its most recent disclosure with the Securities and…- benzinga.com TD Cowen Maintains Buy on AnaptysBio, Lowers Price Target to $70 TD Cowen analyst Joseph Thome maintains AnaptysBio (NASDAQ:ANAB) with a Buy and lowers the price target from $75 to $70.
zacks.com GSK's sBLA for Jemperli Gets FDA Priority Tag in Rectal Cancer GSK's Jemperli gets FDA priority review for dMMR/MSI-H rectal cancer with a decision due in February 2027, while Hibsago wins Japan approval in CHB.
benzinga.com HC Wainwright & Co. Reiterates Buy on AnaptysBio, Maintains $95 Price Target HC Wainwright & Co. analyst Joseph Pantginis reiterates AnaptysBio (NASDAQ:ANAB) with a Buy and maintains $95 price target.
seekingalpha.com AnaptysBio: The Royalty Waterfall Is About To Reverse AnaptysBio is now a focused royalty management company, with its value tied primarily to Jemperli royalties from GSK. Post-spin, ANAB operates virtually with a 95% targeted EBIT margin and over $140M…
defenseworld.net AnaptysBio (NASDAQ:ANAB) Stock Price Up 5.3% – Still a Buy? AnaptysBio, Inc. (NASDAQ: ANAB - Get Free Report) rose 5.3% during mid-day trading on Friday. The company traded as high as $56.54 and last traded at $57.00. 47,244 shares were traded during mid-day…
zacks.com GSK's Jemperli Delivers Promising Interim Data in Rectal Cancer GSK reports positive interim phase II AZUR-1 data as Jemperli meets the primary endpoint in rectal cancer, supporting potential regulatory filings.
benzinga.com FedEx, Cerebras Systems And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session U.S. stock futures mixed, Nasdaq 100 up 100 points. FedEx falls after Q4 results, beating estimates but reporting reduced operating margin. Other stocks also down in pre-market.
benzinga.com HC Wainwright & Co. Assumes AnaptysBio at Buy, Announces Price Target of $95 HC Wainwright & Co. analyst Joseph Pantginis assumes AnaptysBio (NASDAQ:ANAB) with a Buy rating and announces Price Target of $95.
zacks.com Is AnaptysBio (ANAB) Outperforming Other Medical Stocks This Year? Here is how AnaptysBio, Inc. (ANAB) and Electromed, Inc. (ELMD) have performed compared to their sector so far this year.
zacks.com Wall Street Analysts See a 38.75% Upside in AnaptysBio (ANAB): Can the Stock Really Move This High? The consensus price target hints at a 38.8% upside potential for AnaptysBio (ANAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings…
zacks.com AnaptysBio (ANAB) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now After losing some value lately, a hammer chart pattern has been formed for AnaptysBio (ANAB), indicating that the stock has found support. This, combined with an upward trend in earnings estimate…- benzinga.com UBS Maintains Buy on AnaptysBio, Raises Price Target to $76 UBS analyst Michael Yee maintains AnaptysBio (NASDAQ:ANAB) with a Buy and raises the price target from $60 to $76.
- benzinga.com Barclays Maintains Overweight on AnaptysBio, Raises Price Target to $75 Barclays analyst Etzer Darout maintains AnaptysBio (NASDAQ:ANAB) with a Overweight and raises the price target from $63 to $75.
benzinga.com AnaptysBio Q1 EPS $(1.84) Misses $(0.92) Estimate, Sales $25.556M Miss $28.973M Estimate AnaptysBio (NASDAQ:ANAB) reported quarterly losses of $(1.84) per share which missed the analyst consensus estimate of $(0.92) by 100 percent. This is a 43.75 percent decrease over losses of $(1.28)…
globenewswire.com Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today…- benzinga.com AnaptysBio Appoints Christopher Murphy CFO AnaptysBio, Inc. (NASDAQ:ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today announced the appointment of Christopher Murphy as…
globenewswire.com Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors SAN DIEGO, May 11, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today…- benzinga.com Piper Sandler Maintains Overweight on AnaptysBio, Lowers Price Target to $93 Piper Sandler analyst Yasmeen Rahimi maintains AnaptysBio (NASDAQ:ANAB) with a Overweight and lowers the price target from $95 to $93.
- benzinga.com Leerink Partners Maintains Outperform on AnaptysBio, Raises Price Target to $85 Leerink Partners analyst David Risinger maintains AnaptysBio (NASDAQ:ANAB) with a Outperform and raises the price target from $66 to $85.
benzinga.com AnaptysBio Stock Rallies As Delaware Court Tosses Tesaro Breach Claim AnaptysBio shares jump 12% after a favorable Delaware Court ruling in the Tesaro dispute. See the latest technical outlook and more.
benzinga.com XOMA Royalty, Oruka Therapeutics, Repay Holdings And Other Big Stocks Moving Higher On Monday U.S. stocks were lower, Dow Jones fell 0.1% on Monday. XOMA shares rose on Ligand's plans to acquire XOMA for $39.00/share. Other big gainers: MANE, ORKA, OGN, XE, PLBL, SLS, ANAB, EVH, IHRT, RPAY,…
benzinga.com AnaptysBio Wins Court Ruling Upholding Jemperli Royalties, Trial Vs. Tesaro/GSK Set For July 14–17, 2026 Ruling preserves current contracted royalty rates and rejects Tesaro's request for any royalty reductionTrial to adjudicate Anaptys' contract claims and right to seek reversion of Jemperli against…
benzinga.com Barclays Maintains Overweight on AnaptysBio, Lowers Price Target to $63 Barclays analyst Etzer Darout maintains AnaptysBio (NASDAQ:ANAB) with a Overweight and lowers the price target from $79 to $63.- benzinga.com UBS Maintains Buy on AnaptysBio, Lowers Price Target to $60 UBS analyst Michael Yee maintains AnaptysBio (NASDAQ:ANAB) with a Buy and lowers the price target from $90 to $60.
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session - benzinga.com AnaptysBio Completes Spin-Off Of First Tracks Biotherapeutics; Anaptys To Now Exclusively Manage Financial Collaborations For Jemperli With GSK And Imsidolimab With Vanda Focused on protecting and returning value of Jemperli and imsidolimab royalties to shareholdersLaunches with virtual model, including limited FTEs and minimal operating expenses, and approximately…
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
- benzinga.com Piper Sandler Maintains Overweight on AnaptysBio, Raises Price Target to $95 Piper Sandler analyst Yasmeen Rahimi maintains AnaptysBio (NASDAQ:ANAB) with a Overweight and raises the price target from $67 to $95.
- benzinga.com HC Wainwright & Co. Reiterates Buy on AnaptysBio, Maintains $66 Price Target HC Wainwright & Co. analyst Emily Bodnar reiterates AnaptysBio (NASDAQ:ANAB) with a Buy and maintains $66 price target.
- benzinga.com AnaptysBio Announces $100M Buyback Plan; Announces To Manage Financial Partnership For Jemperli With GSK And Imsidolimab With Vanda After Planned Spin-Off Of First Tracks Biotherapeutics AnaptysBio, Inc. (Nasdaq: ANAB) today announced that its Board of Directors has authorized a Stock Repurchase Plan under which the company may repurchase up to $100,000,000 of the company's…
- benzinga.com UBS Maintains Buy on AnaptysBio, Raises Price Target to $90 UBS analyst Michael Yee maintains AnaptysBio (NASDAQ:ANAB) with a Buy and raises the price target from $70 to $90.
- benzinga.com Wedbush Maintains Outperform on AnaptysBio, Raises Price Target to $75 Wedbush analyst Martin Fan maintains AnaptysBio (NASDAQ:ANAB) with a Outperform and raises the price target from $60 to $75.
- benzinga.com Truist Securities Maintains Hold on AnaptysBio, Raises Price Target to $50 Truist Securities analyst John Lee maintains AnaptysBio (NASDAQ:ANAB) with a Hold and raises the price target from $36 to $50.